Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fibromatosis, Gingival, 2 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 18Cyclophosphamide 9fludarabine 8Nivolumab 8cemiplimab 5Carboplatin 5atezolizumab 4Gemcitabine 4Filgrastim 4Drug Therapy 4Docetaxel 4Cisplatin 4palbociclib 3durvalumab 3Paclitaxel 3Interleukin-2 3Bortezomib 3fludarabine phosphate 2epacadostat 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Temozolomide 2SS1(dsFv)PE38 2Riluzole 2Peripheral Blood Stem Cell Transplantation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × seribantumab × Gynecologic × Clear all
NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

Phase 2 Terminated
54 enrolled 11 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡